US Patent

US8975254 — Androgen receptor modulating compounds

Method of Use · Assigned to Orion Oyj · Expires 2033-03-25 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds of formula (I) and their pharmaceutically acceptable salts, as well as compositions and methods of treating with these compounds.

USPTO Abstract

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4208 — Nubeqa

Patent Metadata

Patent number
US8975254
Jurisdiction
US
Classification
Method of Use
Expires
2033-03-25
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.